Browse the evidence

The potential effect of sitagliptin on blood glucose was lost by month 6 after treatment discontinuation.

This suggests that continuous treatment may be necessary to maintain glycemic control.

Monogenic obesity is rare and caused by mutations in a single gene.

Recognizing the rarity of monogenic obesity can help in accurate diagnosis and treatment.

Tirzepatide is a GIP receptor and GLP-1 receptor agonist.

Understanding the mechanism can help in predicting the drug's effects and potential interactions.

Tirzepatide has been registered in multiple countries including the USA, UK, Canada, and Saudi Arabia.

This information is relevant for healthcare providers regarding the availability of Tirzepatide.

In 46% of the 104 studies analyzed, there was no information on the proportion of older individuals.

Practitioners should be cautious when applying findings from studies that do not include older populations.

Older patients were mostly underrepresented in the studies analyzed.

Findings may not be generalizable to older patients due to their underrepresentation.

The analysis found no significant differences in efficacy and safety of the drugs between age groups.

Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors appear consistent across age groups.

Major complication rates did not differ significantly between AOM users and the control group.

AOMs may be safely used preoperatively without increasing complication risks.

No significant differences in readmission rates, BMI, and total weight loss were observed at 6, 12, and 18 months of follow-up between groups.

Long-term outcomes may not be significantly improved by preoperative AOM use.

46% of the 104 studies analyzed lacked information on the proportion of older individuals.

Practitioners should be aware of the lack of representation of older patients in clinical trials when prescribing these medications.

Older patients were mostly underrepresented in clinical trials for GLP-1 receptor agonists and SGLT2 inhibitors.

Practitioners should consider the implications of underrepresentation when treating older patients.

No significant differences in efficacy and safety of the drugs were found between age groups.

Practitioners can consider that the efficacy and safety of these medications do not significantly vary with age.

Common side effects of all GLP-1-agonists include an increased risk of gastrointestinal and gallbladder-related complaints.

Clinicians should be aware of potential gastrointestinal and gallbladder-related side effects when prescribing GLP-1-agonists.

Anti-obesity vaccines are primarily in preclinical to Phase II stages, with candidates like ghrelin vaccines showing up to 15% reduced weight gain in preclinical models.

Ghrelin vaccines may be a promising avenue for reducing weight gain in future therapies.

Somatostatin vaccines achieved 10–13% weight loss in mice.

Somatostatin vaccines may provide a viable option for weight loss in future treatments.

Anti-obesity vaccines face significant immunological and regulatory challenges.

Understanding these challenges is crucial for developing effective anti-obesity vaccines.

Many individuals do not continue therapy indefinitely.

Clinicians should be aware of potential adherence issues with incretin therapy.

Acute administration of 0839 and 0833 dose-dependently reduced food intake in normal weight rats.

Both 0839 and 0833 may be effective in reducing food intake in normal weight populations.

46% of the 104 studies analyzed lacked information on the proportion of older individuals.

Practitioners should be cautious about the applicability of findings to older patients.

Older patients were mostly underrepresented in clinical trials of GLP-1 receptor agonists and SGLT2 inhibitors.

Clinical guidelines may need to consider the lack of data on older patients.

The most common adverse reactions associated with tirzepatide are gastrointestinal disorders.

Healthcare providers should inform patients about potential gastrointestinal side effects when prescribing tirzepatide.

Amylin receptor activation has emerged as a promising drug target for the treatment of diabetes and obesity.

Practitioners should consider amylin receptor activators as a potential treatment option for obesity and diabetes.

The 1998 overweight and obesity clinical guidelines defined overweight as a BMI of 25–29.9 kg/m2 and obesity as a BMI of ≥30 kg/m2.

Practitioners should use these definitions for assessing and managing weight status.

SGLT2i sind etabliert zur Reduktion von Herzinsuffizienzhospitalisierungen und Nierenendpunkten über das gesamte Herzinsuffizienzspektrum.

Clinicians should utilize SGLT2 inhibitors for managing heart failure and kidney disease.